Cizzle Biotechnology Holdings PLC
LSE:CIZ
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Cizzle Biotechnology Holdings PLC
LSE:CIZ
|
6.1m GBP |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.3B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
25.7B USD |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20.9B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
21.2B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
121.4B DKK |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.2B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Cizzle Biotechnology Holdings PLC
Glance View
Cizzle Biotechnology Holdings Plc is a holding company, which is actively seeking for new investment opportunity. The Company’s proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early stage lung cancer. The company helps to reduce the need for repeated computed tomography (CT) scanning. The firm provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response.
